Avatrombopag - Dova Pharmaceuticals

Drug Profile

Avatrombopag - Dova Pharmaceuticals

Alternative Names: AKR-501; AKR-501 monomaleate; Avatrombopag maleate; DOPTELET; E-5501; YM-477

Latest Information Update: 06 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Dova Pharmaceuticals
  • Class Piperazines; Piperidines; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombocytopenia
  • Preregistration Idiopathic thrombocytopenic purpura

Most Recent Events

  • 04 Sep 2018 Preregistration for Idiopathic thrombocytopenic purpura (Treatment-experienced) in USA (PO)
  • 09 Aug 2018 Dova Pharmaceuticals plans to submit a supplemental New Drug Application to the US FDA for Immune thrombocytopenic purpura in the third quarter of 2018
  • 09 Aug 2018 EMA grants a target decision date of July 2019 for Avatrombopag for Thrombocytopenia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top